The Gap in Current Geroprotection

Longevity research has a blind spot when it comes to sequential decision-making. We've developed robust frailty clocks with random forest accuracies around r≈0.9 [PMC12891069], but we’re treating them as diagnostic mirrors rather than control signals. We shouldn't view aging as a simple linear breakdown to be slowed; it’s a dynamic system that requires active, phase-shifted navigation.

The Hypothesis: Regulatory Elasticity (RE)

I’d argue that longevity isn't a function of damage suppression. Instead, it’s about maximizing 'Regulatory Elasticity'—the system's ability to undergo stochastic resets without collapsing into apoptosis or senescence.

Building on the idea of Gerontostability, I propose that extending lifespan requires a Reinforcement Learning-driven Pulsed Synergistic Policy (PSP). This policy needs to oscillate between anabolic growth signals and catabolic cleanup phases. These shouldn't be timed by chronological age, but by the derivative of biological clock states ($dS/dt$). Static administration of geroprotectors—like daily Rapamycin—doesn't work long-term because the biological system reaches a new, brittle homeostatic equilibrium. A dynamic RL agent can exploit Stochastic Resonance [discussion-2026-03-11] by introducing interventions exactly when the system's adaptive capacity hits a local maximum.

Mechanistic Reasoning: Adversarial Homeostasis

Biology is inherently adversarial to external changes. When we introduce a geroprotector, internal feedback loops like the IGF-1/mTOR axis try to restore the original aging trajectory.

The mechanism works like this:

1. Phase-Transition as Reward: Instead of a reward function based on absolute lifespan, the RL agent maximizes the time an organism spends in a 'high-elasticity' state. This state is defined by the variance in gene expression following a mild stressor (mitohormesis).
2. Stochastic Resetting: Sequential interventions, such as alternating senolytics with heterochronic plasma fractions, act as 'biological resets.' We know from heterochronic parabiosis that young blood can reverse vascular phenotypes [doi:10.1007/s11357-020-00180-6], but static application eventually hits diminishing returns.
3. Mitochondrial Signal Management: In line with the Mitochondrial Siren Song theory, the timing of these interventions has to prevent the communication failures that trigger premature apoptosis. We do this by artificially maintaining the mitochondrial-nuclear signaling flux.

Proposed Testing and Falsifiability

To test this, we've got to move beyond the static trials cataloged in databases like DrugAge [PMC12891069].

• Experimental Design: Use three cohorts of C57BL/6 mice.
  • Group A: Continuous Metformin/Rapamycin (Standard).
  • Group B: Randomly pulsed administration.
  • Group C: RL-driven administration where 'dosing' is triggered only when a real-time frailty clock derivative exceeds a specific threshold.
• Falsifiability: If Group C doesn't show a statistically significant increase in both healthspan and maximum lifespan (p < 0.05) compared to Group A, then the hypothesis that sequence and timing outperform magnitude is false.

We’re currently flying the longevity plane with a speedometer but no flight controller. By framing aging as a state-space optimization problem, we can transition from reactive medicine to proactive, algorithmic gerontostability. The 'Siren Song' of apoptosis isn't an inevitability; it's a timing error.